[ad_1] As the first and only PD-L1 immune checkpoint inhibitor approved for aCSCC, UNLOXCYT is an evolution in checkpoint inhibition, offering a balance of durable clinical responses and acceptable tolerability—a key consideration for a patient population that […]
Trending Stories
Checkbook and LianLian Global Announce Strategic Partnership to Power Cross-Border Payments
[ad_1] SAN MATEO, Calif. and NEW YORK, Nov. 25, 2025 /PRNewswire/ — Checkbook, a leading provider of modern digital payment solutions, today announced a strategic partnership with LL Pay U.S., LLC (d/b/a LianLian Global), a […]
Guardians of an ancient migration
[ad_1] BEIJING, Nov. 25, 2025 /PRNewswire/ — A news report from chinadaily.com.cn: For more than 600 years, the people of the Tunpu, fortified villages of the Ming Dynasty (1368-1644), in Anshun city, Guizhou province, have kept […]
From China to the World — Dr. Joe (Yizhou) He and the Architecture of Global Capital’s Next Chapter
[ad_1] BEIJING, Nov. 25, 2025 /PRNewswire/ — A report from 1dai1lu.cn. “The waves are rising on deeper waters.” Dr. Joe (Yizhou) He and the Architecture of […]
Telix Pharmaceuticals (TLX) Hit with Investor Lawsuit Alleging Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability– Hagens Berman
[ad_1] SAN FRANCISCO, Nov. 25, 2025 /PRNewswire/ –Telix Pharmaceuticals Ltd. (NASDAQ: TLX), a commercial-stage biopharmaceutical company specializing in diagnostic and therapeutic radiopharmaceuticals, is now the target of a securities class action lawsuit following a series […]















